BC
SNDX icon

Brookfield Corp’s Syndax Pharmaceuticals SNDX Stock Holding History

Brookfield Corp’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-41,931
Closed -$918K – 770
2021
Q4 		$918K Buy
+41,931
New +$775K ﹤0.01% 463

Other funds holding SNDX

APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Brookfield Corp's SNDX Position: Q1 2022 in Review

Brookfield Corp sold out of Syndax Pharmaceuticals (SNDX) in Q1 2022, closing a stake of 41,931 shares — an estimated $918K sold.

Brookfield Corp first reported a position in SNDX in Q4 2021 and held it in 1 quarter. The position peaked at $918K in Q4 2021. 136 funds tracked by Wall St. Rank hold SNDX as of Q1 2022.

  • Brookfield Corp reported no remaining Syndax Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Brookfield Corp sold 41,931 Syndax Pharmaceuticals shares in Q1 2022, an estimated $918K.
  • Brookfield Corp first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Brookfield Corp's Syndax Pharmaceuticals position peaked at $918K in Q4 2021.
  • 136 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2022.

Based on Brookfield Corp's 13F filing for Q1 2022, filed 16 May 2022.